(MENAFN- EIN Presswire)
PORTLAND, OREGON, UNITED STATES, September 3, 2024 /EINPresswire / -- According to the recent report released by Allied market Research, the global transdermal drug delivery systems market size is predicted to grow to $87,322.40 million by 2030, having gained a value of $52,476.50 million in 2020, showcasing a considerable CAGR of 4.9% from 2021 to 2030. This market report provides a comprehensive analysis of leading investment pockets, top market segments, market dynamics, market size and forecasts, competitive analysis, and regional analysis. It is an essential resource for the stakeholders, and leading market players to strategically plan and enhance their competitive advantage.
Request Sample of the Report on Transdermal Drug Delivery Systems Market Forecast 2032 -
Key Takeaways:
Motion sickness segment is estimated to manifest the highest CAGR of 6.3% from 2021 to 2030.
Asia-Pacific is anticipated to portray the highest CAGR of 6.1% during the forecast period.
The rise in global population has significantly increased the demand for geriatric medicines.
Recent Development in Transdermal Drug Delivery Systems Market
In September, 2022, Corium, Inc., a fully-integrated biopharmaceutical company, announced the launch of ADLARITY (donepezil transdermal system) in the U.S. for the treatment of patients with mild, moderate, or severe dementia of the Alzheimer's type.
In November, 2023, DifGen Pharmaceuticals LLC announced the launch of its second complex Transdermal product, generic Buprenorphine Transdermal System (Gx to Butrans(R)) in the US market.
Want to Explore More, Connect to our Analyst -
The global transdermal drug delivery systems market is categorized into various segments based on type, application, and region. It is offered in both tabular and graphical form, permitting an individual or a commercial organization to benefit perception into the highly profitable and swiftly expanding segments.
By type, the passive segment accounted for the major market share in 2020, acquiring nearly three-fifths of the global transdermal drug delivery systems market revenue. On the other hand, the active segment would cite the fastest CAGR of 5.6% throughout the forecast period.
By application, the analgesics segment garnered the major market share in 2020, holding around one-third of the global transdermal drug delivery systems market revenue. The motion sickness segment, simultaneously, would display the fastest CAGR of 6.3% throughout the forecast period.
For Procurement Information -
By region, the market across North America dominates the largest share in 2020, contributing to more than two-fifths of the global transdermal drug delivery systems market. However, the market across the Asia-Pacific region would exhibit the fastest CAGR of 6.1% throughout the forecast period. The Europe and LAMEA provinces are also studied in the report.
Competitive Landscape:
Viatris Inc.
Bayer AG
Boehringer Ingelheim GmbH
Endo International plc
GlaxoSmithKline plc.
Johnson & Johnson
Novartis AG
Purdue Pharma L.P.
Altaris
Hisamitsu Pharmaceutical Co. Inc.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of“Market Research Reports” and“Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN03092024003118003196ID1108629094
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.